TITLE

Swedish Research Wins US Patent for Maas Biolab

PUB. DATE
December 1999
SOURCE
Worldwide Biotech;Dec99, Vol. 11 Issue 12, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Announces that the United States Patent and Trademark Office granted patent 5,972,924 to Maas Bio1AB of Honolulu, Hawaii, LLC for cyclosporin neuroprotection. Acute brain attacks potentially treatable with cyclosporin; Mechanism of action of cyclosporin; Contact information.
ACCESSION #
2573158

 

Related Articles

  • Grant of Interim Extension of the Term of U.S. Patent No. 5,407,914; SURFAXIN® (Lucinactant). Bahr, Robert W. // Federal Register (National Archives & Records Service, Office of;11/3/2011, Vol. 76 Issue 213, p68166 

    The article announces that the United States Patent and Trademark Office has issued an Order Granting Interim Extension for a third one-year interim extension of the term of U.S. Patent No. 5,407,914 for the human drug product, Surfaxin (lucinactant).

  • News in Brief. Harrison, Charlotte // Nature Reviews Drug Discovery;Dec2007, Vol. 6 Issue 12, p948 

    The article offers world news briefs related to drugs. GlaxoSmithKline has succeeded in obtaining a preliminary injunction that has prevented the U.S. Patent and Trademark Office (PTO) bringing in changes that restrict the number of patent claims and continuations that can be filed. The highest...

  • WEEK IN WASHINGTON.  // BioWorld Insight;8/27/2012, Vol. 20 Issue 35, p6 

    No abstract available.

  • Legislative Background.  // Congressional Digest;Dec96, Vol. 75 Issue 12, p299 

    Provides information about a number of bills introduced during the 104th Congress to alter the organization of the US Patent and Trademark Office ad reform some of its procedures. House legislation; Senate legislation; Other intellectual property rights bills.

  • Should the Patent and Trademark Office Be a Government Corporation? PRO. Lehman, Bruce A. // Congressional Digest;Dec96, Vol. 75 Issue 12, p300 

    Argues for the reorganization of the US Patent and Trademark Office (PTO) as a wholly owned government corporation. Concepts that underlie the US Department of Commerce's approach to the reorganization of the PTO; Structure of the actual patent and trademark examining organization.

  • Should the Patent and Trademark Office Be a Government Corporation? CON. Rohrabacher, Dana // Congressional Digest;Dec96, Vol. 75 Issue 12, p301 

    Argues against the reorganization of the US Patent and Trademark Office (PTO) as a wholly owned government corporation. Protection of private property rights as an inherent governmental function; Privatization of certain government functions; Removal of civil service status for the employees of...

  • Should the Patent and Trademark Office Be a Government Corporation? CON. Hunter, Duncan // Congressional Digest;Dec96, Vol. 75 Issue 12, p305 

    Argues against the reorganization of the US Patent and Trademark Office (PTO) as a wholly owned government corporation. Importance of the patent system; Basic reason for the existence of the PTO; Pantent Office as a core Federal function; Customers of the PTO.

  • More trouble at the US patent office. Fox, Barry // New Scientist;4/23/94, Vol. 142 Issue 1922, p21 

    Reports on United States Patent and Trademark Office's revocation of a basic patent on video tape recording technology it had granted to Eastman Kodak Company. Freeze on patent infringement action filed by Kodak against Sony Corp.; Basis of Kodak's claim; Sony's prior art documents.

  • WEEK IN WASHINGTON.  // BioWorld Insight;10/19/2009, Vol. 17 Issue 42, p7 

    The article reports on the U.S Patent and Trademark Office's cancellation of the proposed rules on patent applications by former Bush administration.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics